Background. Vaccine efficacy (VE) against vulvar human papillomavirus (HPV) infection has not been reported and data regarding its epidemiology are sparse.
Vulvar cancer is rare, accounting for approximately 4% of gynecological malignancies worldwide [1] . However, the incidence of vulvar cancer has been increasing, particularly in young women [2, 3] . In the United States from 2000 to 2009, the incidence of vulvar cancer has significantly increased among both white and African American women; 1.4% and 0.9% annual percentage change, respectively [3] . This increase is believed to be due to a rise in human papillomavirus (HPV) infection [2, [4] [5] [6] . Worldwide, it is estimated that HPV infection is the causative agent in approximately 43% of vulvar cancers [7] . HPV 16 and 18 infections combined account for 93% of HPV-associated vulvar cancers [8] ; thus, prophylactic vaccination has the potential to reduce the incidence of vulvar cancer.
Two vaccines prevent HPV 16 and 18 infections at the cervix: the bivalent HPV16/18 vaccine Cervarix ® , GlaxoSmithKline Vaccines [GSK]) [9] and the quadrivalent HPV6/11/16/18 vaccine (Gardasil™, Merck and Co, Inc) [10] . Data presented in abstract form for the bivalent vaccine reported a 75% reduction in HPV16/18-associated vulvar/vaginal precursor lesions (a combined endpoint) among vaccinated women compared to controls [11] . For the quadrivalent vaccine, high (>95%) vaccine efficacy (VE) against HPV16/ 18-associated vulvar intraepithelial neoplasia grades 1, 2, and 3 was demonstrated [10] , garnering an indication from the US Food and Drug Administration (FDA) for prevention of vulvar cancer. VE against HPV16/18 infections at the vulva has yet to be reported. Efficacy against HPV16/18-associated vulvar lesions was demonstrated by both pharmaceutical vaccine trials using HPV DNA testing of vulvar lesions, which represented a small subset of the total trial population [10, 11] . Given that VE against HPV-associated lesions is the result of prevention of HPV infection, we reasoned that use of a virologic endpoint for the estimation of vulvar VE would provide additional novel information on an intermediate endpoint on the pathway to cancer.
Likewise, perhaps due to the rarity of HPV-associated vulvar cancer, only 6 studies have been published on the epidemiology of vulvar HPV infection in cancer-free women [12] [13] [14] [15] [16] [17] and only 1 study reported risk factors associated with high-risk HPV infection of the vulva [17] . To address the limited knowledge of vulvar VE as well as the epidemiology of vulvar HPV infection, we implemented a vulvar specimen collection at the final (year 4), randomized blinded study visit of the Costa Rica Vaccine Trial (CVT). The goals of this value-added analysis were to (1) estimate the reduction of prevalent HPV16/18 infections at the vulva compared to cervix among HPV vaccinated women compared to controls 4 years after vaccination, and (2) characterize the prevalence of and risk factors for vulvar HPV infection in the control arm of this study population.
METHODS

Subject Participants and Study Design
Women included in the present evaluation are participants in both arms of a double-blind, controlled, randomized, phase III study of the efficacy of an HPV16/18 virus-like particle vaccine conducted in CVT. This trial was designed to evaluate VE against persistent cervical HPV16/18 infection and precancerous lesions, as previously described [18] . Inclusion criteria were: age 18-25 years (inclusive) at entry, generally healthy as determined by medical history and a physical examination, not pregnant or breastfeeding, using contraception (including abstinence) during the vaccination period, and willing to provide written informed consent. The trial was reviewed and approved by human subjects review committees of INCIENSA (Instituto Costarricense de Investigacion y Enseñanza en Nutrición y Salud) in Costa Rica and the National Cancer Institute in the United States. All subjects provided informed consent.
Procedures
At enrollment, women were blindly randomized to receive the HPV bivalent vaccine (Cervarix ® , GSK Vaccines) or a control hepatitis A vaccine (modified Havrix™, GSK Vaccines) [19, 20] . At enrollment and at each annual visit, a questionnaire regarding the woman's education, marital status, sexual and reproductive history, and smoking habits was administered; a pelvic examination was performed on sexually experienced women, with collection of cervical cells for liquid-based cytology and HPV testing; and blood was collected for HPV16/18 serology. Women with low-grade cervical cytologic abnormalities were evaluated semiannually and those with high-grade or persistent low-grade cervical abnormalities were referred for colposcopy and treatment as needed [18] . A medical history was conducted during enrollment and during each follow-up visit as part of the process of assessment of adverse events, and information regarding medical conditions (including those that affect the female reproductive tract) was collected by study clinicians at each follow-up visit. At the 4-year study visit, an additional questionnaire regarding sexual history (including oral and anal sex) was administered, and all sexually experienced women were asked to provide a vulvar, cervical, and anal specimen, which were collected by study clinicians.
Specimen Collection
Prior to insertion of the speculum for cervical specimen collection, a vulvar sample was collected by swabbing the mucosal surface of each labia minora 4 times (for a total of 8 swipes using a single Dacron swab). The vulvar swab was placed in a vial of 1 mL PreservCyt and frozen in liquid nitrogen. Cervical specimens were collected with a Cervex-Brush (Rovers Medical Devices) by firmly rotating the brush 5 times 360°around the cervical os. The Cervex-Brush was placed in 20 mL PreservCyt, and 0.5 mL aliquots for HPV polymerase chain reaction (PCR) testing were prepared and frozen at the local laboratory following PCR-safe procedures.
HPV DNA Testing
A total of 5404 women agreed to both vulvar and cervical specimen collection at the 4-year study visit (when women were between the ages of [22] [23] [24] [25] [26] [27] [28] [29] . All 5404 cervical samples were tested for HPV DNA. The first 1044 of the 5404 vulvar samples collected were tested for HPV DNA; additional samples were not tested due to financial constraints. The same HPV DNA testing procedures were used for both the cervical and vulvar specimens, and all samples were tested within the same laboratory. DNA extraction via the MagNAPure LC DNA isolation procedure (Roche Diagnostics) was used. Extracted DNA samples were tested for HPV DNA using the HPV SPF 10 PCR-DEIA (DNA enzyme immunoassay)-LiPA 25 (line probe assay) version 1 system (Labo Biomedical Products, Rijswijk, The Netherlands) [21, 22] . Briefly, this broad-spectrum PCR-based HPV DNA testing system uses SPF 10 primers to amplify and a DEIA to detect at least 69 HPV genotypes and the LiPA 25 line probe assay to genotype carcinogenic and noncarcinogenic HPVs. To increase the sensitivity of type-specific detection of HPV16 and 18 using the SPF 10 DEIA system, all specimens positive for HPV DNA using SPF 10 DEIA but negative for HPV16 or HPV18 by LiPA 25 were additionally tested with type-specific primers [23] .
Statistical Analysis
General characteristics from the 4-year postvaccination visits were compared between women who had (1) a vulvar sample collected and tested, (2) a vulvar sample collected and not tested, and (3) refused vulvar sample collection. Groups were compared using a χ 2 test. Restricting to women who had a vulvar sample collected and tested (group 1 above), both enrollment and 4-year postvaccination characteristics between women in the vaccine and control arms were compared using a χ 2 test
(Supplementary Table 1 ). Our approach to calculating VE at extra-cervical sites at the 4-year study visit has been previously published [19, 24] . We evaluated prevalence of vulvar HPV16 or 18 infections approximately 4 years after vaccination (defined as detection of either HPV16 or HPV18 or both at the 4-year study visit); cervical HPV16 or 18 infections among the same women at the same time point were evaluated for comparison purposes. Our intention-to-treat analytic cohort ( Figure 1 ) included all women who had vulvar specimens collected and had HPV results available; no exclusions were made based on enrollment HPV DNA positivity, HPV serostatus, or number of vaccine doses received. While we desired to create an additional HPV-naive analytic cohort (defined as HPV negative at the cervix at baseline), we did not have adequate power to pursue this analysis. For each arm, the prevalence of HPV16/18 measured 4 years postvaccination were expressed as the number of infected women per 100 women vaccinated (stratified by HPV vs control vaccine); asymptotic confidence intervals (95% confidence interval [CI]) are reported. The complement of the ratios of the prevalence for the HPV and control arms comprised the VE estimates. Exact confidence intervals for VE were calculated based on the binomial distribution of the number of events in the HPV arm among the Four women received discordant vaccines (1 woman was enrolled twice and received 3 doses of each vaccine and 3 women received 2 doses of 1 vaccine and 1 dose of the other vaccine). For the aim of this analysis, the women were assigned to the group for which the first dose was given.
b Data obtained at the 4-year study visit at which vulvar specimens were obtained were used to create the full analytic cohort.
total number of events in the HPV and control arms [25, 26] . Vulvar and cervical VE estimates were calculated and compared by including an arm*anatomical site interaction variable in a generalized estimating equation model [27] and evaluating whether the β coefficient for the interaction variable varied significantly from zero, a nonsignificant P value would be interpreted as the 2 VE estimates are not significantly different.
The epidemiology of vulvar versus cervical HPV infection was evaluated in the control arm. Prevalence of vulvar and cervical HPV were described separately among all women. Analyses for grouped HPV infections (any HPV, carcinogenic, noncarcinogenic HPV) were conducted at the woman-level; for analyses by individual HPV type, a woman could only contribute once to each analysis. A κ statistic was calculated for vulvar and cervical HPV infection for each of the 25 HPV types. McNemar's test was used to determine κ significance. In cases of less than 5 events per cell, χ 2 tests were used instead.
Risk factors for vulvar HPV infection were evaluated in the control arm only using logistic regression analysis. Variables evaluated in univariate modeling included: age, education, marital status, smoking status, age at first vaginal intercourse, lifetime number of sexual partners, and total number of years sexually active. The association between vulvar HPV and medical conditions of the female reproductive tract was also evaluated. To evaluate the independent determinants of vulvar HPV, risk factors that were significantly associated with vulvar HPV in the univariate analysis or considered important based on the literature (ie, age and lifetime number of sexual partners) were included in multivariate models as adjusted odds ratios (aORs). The same analyses were conducted using cervical HPV as the outcome. For all analyses, a P value < .05 (2-tailed) was considered statistically significant.
RESULTS
Participant Characteristics
Of the 7466 women randomized (Figure 1) , 6351 attended the 4-year study visit (3180 HPV arm; 3171 Control arm). Sexually naive women were not eligible for vulvar specimen collection (n = 382). Of the eligible women (n = 5969), 565 (297 HPV arm; 268 Control arm) women refused vulvar specimen collection and 5404 accepted (90.5%). Of the 5404 women that provided a vulvar specimen, the first 1044 samples were tested for HPV DNA (508 HPV arm; 536 Control arm).
Compared to women whom had a vulvar sample collected (n = 5404), women who refused vulvar sample collection (n = 565) appeared generally less sexually experienced, a finding we expected based on previous work (Table 1 ) [19] . Participant characteristics were similar for women for whom the vulvar sample was HPV tested (n = 1044) and women for whom the vulvar sample was not HPV tested (n = 4360) with regard to age, education level, marital status age at first vaginal intercourse, total number of years sexually active and cervical HPV status. However, women in our analytic cohort (n = 1044) were more likely to be never smokers (82.9% vs 78.8%) and to have fewer number of lifetime sexual partners (median number of sexual partners 2 vs 3) compared to women for whom the vulvar sample was not HPV tested. Distributions of pre-and postrandomization characteristics were similar in the HPV and control arms; all P values were > .3 (Supplementary Table 1 ).
Reduction of Prevalent HPV16/18 Infection Among HPV-Vaccinated Women at the 4-Year Study Visit
Significant VE against prevalent HPV16/18 infection at the 4-year study visit was observed both at the vulva and cervix. Vulvar VE was 54.1% (95% CI, 4.9-79.1; 10 and 23 events in the HPV and control arms, respectively); the corresponding cervical VE was 45.8% (95% CI, 6.4-69.4; 19 and 37 events in the HPV and control arms, respectively). Vaccine efficacy at the vulva did not differ significantly from vaccine efficacy at the cervix; p for anatomic-site interaction = 0.6 ( Table 2) . In order to test the representativeness of our subset of 1044 women compared to the full cohort of women who provided a vulvar sample, we compared cervical VE for both cohorts. While participant characteristics between the 2 groups were similar (Table 1) , cervical VE for the full cohort (n = 5404) was higher than the subset (n = 1044); 71.7% (95% CI, 62.6-78.9) versus 45.8% (95% CI, 6.4-69.4), respectively, albeit with overlapping confidence intervals.
Vulvar HPV Prevalence and Type Distribution
To further our understanding of vulvar HPV epidemiology, we conducted additional prevalence and risk factor analyses in the control arm only. Overall prevalence of any HPV type at the vulva was 29.5% (95% CI, 25.6-33.5; 158 HPV infections detected) ( Table 3 ). The prevalence of carcinogenic and noncarcinogenic HPV types was 16.8% (95% CI, 13.7-20.2) and 17.2% (95% CI, 14.1-20.6), respectively, the total of which exceeds the overall prevalence (29.5%) due to detection of multiple infections. The most common carcinogenic HPV types were HPV52 (3 A κ statistic was computed in order to determine the correlation between vulvar and cervical HPV16 infection within the same women in the control arm only (n = 536). Participant characteristic were compared for women who accepted vulvar sample collection (N = 5404) versus women who refused vulvar sample collection (N = 565). Among women who agreed to vulvar sample collection (N = 5404), participant characteristics were compared for women for whom the vulvar sample was HPV tested (N = 1044) versus not HPV tested (N = 4360).
Missing values accounted for less than 2 percent of the full cohort; yet, when a value was missing: *includes women with a missing value, those who refused to respond, and those who responded "don't know" for this variable; **includes women who did not have missing values for a related variable above, yet had a missing value, refused to respond or responded "don't know" for this variable.
Abbreviations: HPV, human papillomavirus; IQR, interquartile range. a χ 2 P value.
b Any HPV infection detected (carcinogenic and/or noncarcinogenic). A total of 16 vulvar and 25 cervical HPV16 infections were detected. Of the 16 women with a vulvar HPV16 infection, 13 women had a concurrent HPV16 cervical infection. Twelve of 25 women had cervical HPV16 infection only.
Moderate correlation was observed between vulvar and cervical HPV16 infection; κ = 0.6, P = .02. For each of the additional 24 HPV types tested within the control arm, κ ranged from 0.2 to 0.7. Missing values accounted for less than 2 percent of the full cohort; yet, when a value was missing: *includes women with a missing value, those who refused to respond, and those who responded "don't know" for this variable; **includes women who did not have missing values for a related variable above, yet had a missing value, refused to respond or responded "don't know" for this variable.
Statistically significant variables in the multivariate model are bolded.
ORs were adjusted for all the variables in bold.
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; HPV, human papillomavirus; OR, odds ratio; Ref, reference. a Smoking was not significant in the multivariate model and was therefore dropped from the final model.
Risk Factor Analysis
The evaluation of risk factors for any vulvar or cervical HPV was again restricted to the control arm ( 
DISCUSSION
This analysis of data from our randomized, community-based HPV vaccine trial in Costa Rica shows that the bivalent HPV vaccine is efficacious against vulvar HPV16/18 infections in young women measured 4 years after vaccination, and that the observed protection at the vulva is comparable to that observed at the cervix. Due to this being an intention-to-treat analysis conducted at 1 time point within a population that includes HPV-exposed women, vulvar VE estimates in our study are lower than what would be expected among the target vaccination population of HPV-naive adolescents where cervical VE is estimated to approach 100% [28] . However, given that our estimates of cervical and vulvar VE were comparable, we expect based on our study that vulvar VE among HPV-naive adolescents would be as high as cervical VE. Based on the cumulative work to date in our trial, we now understand the HPV vaccine protects against HPV infections at the anatomic sites where HPV causes cancer in women, including the cervix [20] , vulva, anus [19] , and oral region [24] . In this study, we utilized HPV infection as the outcome due to the rarity of vulvar dysplasia. Thus, understanding the epidemiology of vulvar HPV infection provides an important framework for interpreting our vaccine efficacy results. There have been 6 studies published on the epidemiology of vulvar HPV infection in cancer-free women [12] [13] [14] [15] [16] [17] . In our study of young women within the control arm, detection of vulvar HPV was relatively common and mirrored that of the cervix; overall prevalence of HPV among women approached 30%. Both carcinogenic and noncarcinogenic HPV were similarly prevalent (approximately 17%); HPV16 was one of the more common of the carcinogenic types detected (3.0%). The strongest risk factor for vulvar HPV in our study and in a comparable study by Howell-Jones et al [17] was higher number of sexual partners, a finding in line with what is known for cervical HPV epidemiology. Age was another important risk factor for vulvar HPV infection: our point prevalence of vulvar HPV16 was highest among our youngest women (5.9% among 22-23 year olds compared to 1.9% among women ≥28 years old), which is comparable to previously reported prevalence estimates in the literature [12] [13] [14] [15] [16] [17] . Thus, it appears that age-specific vulvar HPV prevalence parallels that of cervical HPV prevalence, which peaks shortly after sexual debut.
There are important considerations in our study. First, in contrast to using precancerous lesions as an outcome, or even persistent HPV infection, 1-time HPV detection is unable to distinguish true vulvar HPV infection from viral deposition from either recent sexual contact or, cervical HPV infection. In this study, half of the 25 women with cervical HPV16 infection had concurrent vulvar infection detected, suggesting that viral deposition from a cervical infection may not be as common as expected. Measures taken to reduce contact of the vulvar specimen with cervical fluids (the vulvar sample was collected prior to insertion of the speculum for cervical specimen collection) may have reduced this potential problem. Second, while we wanted to conduct an additional analysis of vulvar VE in an HPV-naive cohort (based on cervical HPV status at initial vaccination), there were not adequate endpoints to pursue this analysis. Third, not all vulvar samples were HPV tested. The descriptive characteristics of the tested subset were mostly similar to that of the full cohort with vulvar specimen collection; yet, notable differences in cervical VE between the 2 groups suggest the presence of residual variability not captured by our questionnaire. If the tested subset was less risky compared to the full cohort (evidenced by having fewer lifetime sexual partners), then the vulvar VE estimates could have been inflated by the majority of infections detected being incident and therefore preventable by vaccination. If our analytic subset was more risky (evidenced by the higher cervical VE observed in the full cohort), then the opposite could be observed: more prevalent infections at baseline would result in a decrement in the observed VE [29] . While our subset of 1044 may have not been representative of the full cohort, balance was observed between arms; thus, we believe this work yields valid estimates. In the subset, VE estimates for the cervix and the vulva were similar, which we interpret to mean that the vaccine comparably protects against HPV16/18 infections at both anatomic sites.
Our findings suggest that the bivalent HPV vaccine protects against vulvar HPV16 and 18 infections. Findings presented here and in the literature suggest that the incidence of HPV infection and resultant cancers will decrease at several anatomic sites in women who receive the prophylactic HPV vaccines before exposure to the virus [20] . Unfortunately, among unvaccinated women, vulvar HPV infection will remain common.
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